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Inﬂammation plays a critical role in the development of cancer. Matrix Metalloproteinase (MMP) functions in the remodeling of
the extracellular matrix that is integral for many normal and pathological processes such as morphogenesis, angiogenesis, tissue
repair, and tumor invasion. The tissue inhibitor of metalloproteinases (TIMPs) family regulates the activity of multifunctional
metalloproteinases. In this paper, we discuss the role and mechanism of MMP and TIMP in regulating inﬂammation responses
in solid tumors. We discuss the mechanism of MMP and inﬂammation in melanoma, colon cancer, breast cancer, and prostate
cancer. We highlight the roles of the TIMP-2 in modulating the proinﬂammatory NF-κB pathway in melanoma and lung caner
cells. Based on the molecular mechanisms of TIMPs and MMPs in inﬂammation and cancer, we can design new strategies for
cancer therapy.
1.Introduction
MMPs belong to a family of structurally related proteolytic
enzymesthatmediatedegradationoftheextracellularmatrix
and the basement of membranes [1–3]. High levels of
MMP activity have been linked to tumor growth, invasion,
and angiogenesis inﬂammation and may even work in
a nonproteolytic manner [4, 5]. The tissue inhibitor of
metalloproteinases family, including TIMP-1, 2, 3, and 4,
regulates the activity of multifunctional metalloproteinases
[6, 7]. Among TIMP members, TIMP-2 is most frequently
investigated because it is a unique member of the TIMP
family and involved in cancer progression and metastasis.
Recentstudieshavebeguntounravelmolecularpathways
linkinginﬂammationandcancer[8,9].Inﬂammatorycondi-
tions can initiate or promote oncogenic transformation and
geneticandepigeneticchangesinmalignantcells.Aninﬂam-
matory microenvironment further supports tumor progres-
sion [10–12]. Cancer-associated inﬂammation is marked by
thepresenceofspeciﬁcinﬂammatorycellsandinﬂammatory
mediators, including cytokines and chemokines. Nuclear
factor-κB( N F - κB) transcription factor plays an essential role
in innate and adaptive immune responses, cell proliferation,
apoptosis, and tumorigenesis [13–15]. Constitutive activa-
tion of NF-κB has been directly implicated in tumorigenesis
of various cancer types [16–18]. Recent evidence also sug-
gestsacrucialroleforsignaltransducerandactivatoroftran-
scription (STAT) family in selectively inducing and main-
taining a procarcinogenic inﬂammatory microenvironment,
both at the initiation of malignant transformation and dur-
ing cancer progression [11]. The targeting of inﬂammatory
mediators (chemokines and cytokines, such as TNF-α and
IL-1β), key transcription factors involved in inﬂammation
(such as NF-κB and STAT), or inﬂammatory cells decreases
the incidence and spread of cancer [10]. Therefore, anti-
inﬂammation is an essential strategy for the cancer therapy.
In this paper, we discuss the mechanisms of MMPs
and TIMPs in regulating inﬂammation in the cancer cells.
We highlighted the interaction among TIMPs, MMPs, and
inﬂammatory pathways. We focus on the roles of MMP and2 Journal of Signal Transduction
TIMP-2inmodulatinginﬂammationandcancerprogression
in solid tumors. We also discuss the progress on the thera-
peutic researches and lessons learned from the failed clinical
trials for MMP inhibitors. Increasing studies demonstrate
thatchronicinﬂammationisassociatedwithoutcomeofcan-
cers [19]. Therefore, insights in the molecular mechanisms
of MMP and TIMP in inﬂammation and cancer will provide
promising opportunities for therapeutical intervention.
2. MMPs andTIMPs
The MMP family includes over 20 zinc-dependent enzymes
thatsharecommonfunctionaldomains.Theseenzymeswere
initially characterized by their extensive ability to degrade
extracellular matrix proteins including collagens, laminin,
ﬁbronectin, vitronectin, aggrecan, enactin, tenascin, elastin,
and proteoglycans [20]. Recent studies further demonstrate
that MMPs actually cleave many other types of peptides and
proteins and have a myriad of other important functions
independent of proteolytic activity [21].
The tissue inhibitors of metalloproteinases or TIMPs
consist of a small family of four homologous and low
molecular weight proteins. TIMPs suppress MMP activity
critical for extracellular matrix turnover associated with
both physiologic and pathologic tissue remodeling. TIMP
concentrations generally far exceed the concentration of
MMPs in tissue and extracellular ﬂuids, thereby limiting
their proteolytic activity to focal pericellular sites [22].
TIMPs, aside from inhibition MMP, also are involved in
other biological process required for metastasis and angio-
genesis [23]. TIMP-2, a unique member of this family, was
discovered in 1989 [24]. TIMP-2 selectively blocked human
microvascular endothelial cell growth in vitro in response
to proangiogenic factors such as ﬁbroblast growth factor
2(FGF-2) or vascular endothelial growth factor A (VEGF A)
[25]. Other distinguishing features of TIMP-2 are that it is
the only member that is not nested within the gene structure
ofthesynapsingenefamilyandthe timp-2genealsocontains
a large ﬁrst intron (>60kB). TIMP-2 could suppress receptor
tyrosine kinase signaling independent of metalloproteinase
inhibition [25]. TIMP-2 bridges the interaction between the
MMP-2 zymogen and MT1-MMP. In contrast to the usual
inhibitory role, at low TIMP-2 concentration, an adjacent
TIMP-2-free MT1-MMP can eﬀectively activate proMMP-
2. However, at high TIMP-2 concentration, all of the
cell surface MT1-MMP undergoes complex formation with
TIMP-2, thereby inhibiting proMMP-2 activation [26]. The
cellular mechanism for the control of MT1-MMP catalytic
activityinvolvedconcurrentreciprocalmodulationofTIMP-
2 expression by ERK1/2 and p38 MAPKs. Inhibition of
ERK1/2phosphorylationdecreasedTIMP-2production,and
downregulation of p38 MAPK activity enhanced TIMP-2
synthesis [26]. Recently, TIMP-1 is shown to bind to CD63,
thus regulating cell survival and polarization [27]. TIMP3
is also assigned a new function independent of its MMP-
inhibitory activity [28]. TIMP3 blocks the binding of VEGF
to VEGF receptor-2 and inhibits downstream signaling and
angiogenesis [28].
3. GeneralRolesofMMPsandTIMPsinCancers
Tumor cells produce enzymes that destroy the matrix
barriers surrounding the tumor, permitting invasion into
surrounding connective tissues, entry and exit from blood
vessels, and metastasis to distant organs. Enzymes that
degrade the extracellular matrix (ECM) have long been
viewed as essential for tumor progression. MMPs are
able to degrade virtually all ECM components. Therefore,
classically, MMPs were recognized as being produced and
secreted by tumor cells, degrading basement membrane
and extracellular matrix components, thereby facilitating
tumor cell invasion and metastasis. Now, we know that
MMPsarefrequentlyproducedbysurroundingstromalcells,
includingﬁbroblastsandinﬁltratinginﬂammatorycells.One
explanation for this phenomenonis thatcancercellsproduce
ExtracellularMatrix MetalloproteinaseInducer,acellsurface
glycoprotein,whichdirectlystimulatesﬁbroblaststoproduce
MMP1, 2, 3, and MMP14 [29].
Recent studies further demonstrate that MMPs con-
tribute to multiple steps of tumor progression in addition
to invasion, including tumor promotion, angiogenesis, and
the establishment and growth of metastatic lesions in distant
organsites.MMPsareupregulatedinvirtuallyallhumanand
animal tumors as well as in most tumor cell lines [20, 30].
The stage of tumor progression is positively correlated with
the expression of MMP family members (MMP-1/interstitial
collagenase; MMPs 2, 3, 7, 9, 11, and 14) [21]. Moreover,
MMPs also solubilize cell surface and matrix-bound factors
that can then act in an autocrine or paracrine manner
to inﬂuence cellular properties such as growth, death, and
migration. Changes in MMP levels can markedly aﬀect
the invasive behavior of tumor cells and their ability to
metastasize in experimental animal models [31]. Taken
together, these studies suggest that MMPs are important
contributors to tumor progression.
TIMPs are originally known to inhibit the MMP activ-
ities. TIMP is downregulated or silenced in a variety of
human cancer cell lines. TIMPs also are involved in other
biological processes in cancer. Promoter hypermethylation
and lost expression of TIMP-2 gene have been reported
in prostate cells and tumor samples [32]. Overexpression
of TIMPs reduced experimental metastasis of melanoma
[33, 34]. Intraperitoneal injection of recombinant TIMP-1
is explored in lung cancer [35]. Transgenic studies reveal
that mouse 3T3 cells became tumorigenic after antisense
depletion of TIMP-1 [36]. TIMP-1 overproduction slowed
chemical carcinogenesis in skin and liver carcinogenesis in
transgenic mice [37, 38]. In addition, TIMPs have shown
apoptosis-inducing properties (TIMP3). Overexpression of
TIMP-3 resulted in apoptosis of A549 lung cancer cells
and AdCMVTIMP3 up-regulated the expression of p53,
Fas ligand, TNFR1, and TNFR2 on these cells. Adenoviral
delivery of TIMP-3 gene inhibited the growth of pre-
established A549 tumours in Balb/c nude mice, and was
associatedwithagreatertherapeuticeﬀectthaneitherTIMP-
1 or -2 gene delivery. These ﬁndings establish the potential of
adenoviral gene delivery of TIMP3 as a therapeutic agent for
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Figure 1: TIMP-2 expression and NF-κBa c t i v i t y .T h ee ﬀects of
TIMP-2 on the NF-κB pathway include the decreased basal level
of IκBα, increased phosphorylation of IκBα and NF-κB, increased
transcriptionalNF-κBactivity,andelevatedIL-8levelsintheTIMP-
2-overexpressed cells.
demonstrates that the expressions of MMP-1, MMP-2,
MMP-3,MMP-9,urokinase-typePA,andtissue-typePA,and
inhibitors(TIMP-1andTIMP-2)werestrongerorequivalent
in tumor cells than in ﬁbroblasts or inﬂammatory cells
withinthetumorsection[40].Overall,studiesonMMPsand
TIMPS in cancer provide the rationale for developing cancer
drugs that target TIMP and MMP activities.
4. MMPs andCytokines
The activity of MMP is under tight control at several
levels in vivo: transcriptionally by growth factors, hormones,
cytokines, and oncogenes; posttranscriptionally by alteration
of mRNA stability; and at the enzymatic activity level by
activation of the latent form and inhibition by TIMPs [23].
MMPs are generally expressed in very low amounts and
their transcription is regulated either positively or negatively
by cytokines and growth factors such as inﬂammatory
interleukins (IL-1, IL-4, IL-6, TNF) or transforming growth
factors (EGF, HGF, TGFβ)[41]. The importance of cytokines
such as TNF-α, interleukin (IL)-1, and IL-6 in stimulating
production of MMPs in disease has been emphasized. They
can be seen as important therapeutic targets for intervention
incancers.IncreasingevidencesdemonstratethatMMPsplay
an important role in acute as well as chronic inﬂammation
[5, 42]. CCL8/MCP-2 is processed by MMP-1 and MMP-
3. The proteolytic cleavage of CCL8 can counteract the
antitumor capacity of this chemokine in a melanoma model
[43]. The proteolytic cleavage of a chemokine by MMPs can
have great impact in a clinically relevant setting of tumor
development [5].
The transcription of TIMPs is regulated by similar
cytokines and growth factors that control MMP expression,
that is, TGFβ,T N F α,I L - 1 ,a n dI L - 6[ 44]. However, in
macrophages IL-4 and IFN gamma released by lymphocytes
suppress metalloproteinase biosynthesis without aﬀecting
TIMP production [45, 46].
IL-10 is a cytokine with potent anti-inﬂammatory prop-
erties, repressing the expression of inﬂammatory cytokines
such as TNF-alpha, IL-6, and IL-1. IL-10 enhances TIMP-
1 production while decreasing metalloproteinase biosyn-
thesis in tissue macrophages, and blood monocytes TIMP-
2 production was not aﬀected. IL-10 regulation was cell
type speciﬁc, as it had no eﬀect on the production of
metalloproteinases or TIMP by human ﬁbroblasts [47]. In
nonimmortalized primary human prostate cell strains, IL-
10 activation of the IL-10 receptor blocked MMP-2 and
membrane type 1 (MT1)-MMP transcription and protein
synthesis. IL-10 induced protein(s) binding to a putative
“silencer element” downstream of the p53 binding site. The
data show that IL-10 blocks IGF-I activation of MMP-2
and MT1-MMP mRNA expression and protein synthesis
in prostate cells [48]. In summary, IL-10 has a potent
and unique eﬀect by enhancing TIMP production while
decreasing metalloproteinase biosynthesis in cells.
5. TIMP-2 DirectlyModulates the NF-κB
Pathway Activity
NF-κB is an inducible dimeric transcription factor com-
posed of the RelA (p65) and NF-κB1 (p50) subunits [49].
NF-κB activation involves its release from its inhibitor, IκBα,
and its subsequent translocation from the cytoplasm to the
nucleus, where it binds to promoters of target genes. Many
proinﬂammatory cytokines and chemokines, such as IL-8,
IL-6, and TNF, are targets of NF-κB regulation [50, 51].
Using stable melanoma cell lines, parental A2058, A2058T2-
1 overexpressing TIMP-2, and A2058T2R-7 underexpressing
TIMP-2, we demonstrate that the IL-8 secretion and IL-8
mRNA expression signiﬁcantly increased in the A2058T2-
1 overexpressing TIMP-2 [52]. We also found that in the
TIMP-2 overexpressed cells the basal level of IκBα was lower
than that in the parental A2058 cells. IκBα degradation
involves phosphorylation, ubiquitination, and subsequent
proteasomal degradation. Phospho-IκBα was increased in
the TIMP-2 over-expressed cells, which is consistent with
the reduced level of total IκBα. TIMP-2 expression is able
to elevate p65 phosphorylation, thus increasing the NF-
κBa c t i v i t y( t o t a lI κBα ↓ =p-IκB α ↑ = p-p65↑ = activity
of NF-κB↑). TIMP-2 expression directly upregulates the
transcriptional activity of NF-κB[ 52].
Apoptosis is one of the biological eﬀects regulated
by the NF-κB pathway. TIMP-2 overexpression is able to
protect cells from apoptosis. TIMP-2 was shown to stimulate
proliferation in human cells, including osteosarcoma cells
[53], ﬁbroblasts [54], and A549 lung adenocarcinoma cells
[55]. Our data suggest that TIMP-2 over-expression is able to4 Journal of Signal Transduction
protectcellsfromapoptosis inhumanmelanomaA2058cells
[52]. It is consistent with the previous studies that TIMP-2
overexpression protects B16F10 melanoma cells from apop-
tosis reduced [23]. Overall, these data indicate that TIPM-
2 modulates other relevant aspects of the melanomatatic
phenotypes including cell proliferation and cell survival.
In lung cancer cells, the NF-κB activity was increased by
exposure to TIMP-2 [56]. The NF-κB transcription factor
is known to act as a tumor promoter. It is intriguing
that TIMP-2 upregulates NF-κB activity, whereas TIMP-2-
overexpression can prevent tumor invasion [23]. TIMP-2
upregulation of NF-κB activity may inhibit tumor growth in
the early stage because other data suggest a dual function of
NF-κB during tumor progression. In the early stages, NF-κB
inhibits tumor growth; as further mutations lead to a loss
of tumor suppressor expression, the oncogenic functions of
NF-κB become unleashed, allowing it to actively contribute
to tumorigenesis [57].
Overall, TIMP-2 expression can directly modulate the
NF-κBp a t h w a y( Figure 1). The eﬀects of TIMP-2 on the
NF-κB pathway include the decreased basal level of IκBα,
increased phosphorylation of IκBα and NF-κB, increased
transcriptional NF-κBa c t i v i t y ,a n de l e v a t e dI L - 8l e v e l si n
the TIMP-2-overexpressed A2028T2-1 cells. Consequently,
TIMP-2 over-expression was able to protect cells from
apoptosis [52]. Our results and other’s publications show
that TIMP-2 over-expression is suﬃcient to increase the
NF-κB activity and protect cells from apoptosis. These data
emphasize the critical role of TIMP-2 in modulating cell
survival and invasion through the NF-κBa c t i v i t y .
6.STAT, MMPs,andTIMPs
The signal transducers and activators of transcription
(STATs) are members of a ubiquitously expressed family of
transcription factors activated in response to growth factors
and cytokines. STAT3 has been shown to be an oncogene
[58]. Many types of human cancers express constitutively
active STAT3 [58]. Increasing evidences demonstrate that
STAT regulates MMPs [59]. STAT3 up-regulates TIMP-1 in
certaincelllines.Forexample,Asigniﬁcantassociationexists
between the expression of the phosphorylated/active form of
STAT3 (pSTAT3) and that of TIMP1. Importantly, STAT3
activation correlated signiﬁcantly with a lower frequency
of vascular and lymphatic invasion. STAT3 activation may
modulate tumor invasiveness of breast cancer by regulating
TIMP1 expression [60].
TIMP-1 gene is up-regulated by IL-6 [61]. A molecular
biology study identiﬁed that TIMP-1 is a downstream target
of STAT3. Timp-1 gene possesses an IL-6/oncostatin M
(OSM) response element. Within this element, there are two
functional binding sites for transcription factors activator
protein-1 (AP-1) and STAT. IL-6/OSM stimulation induces
binding of STAT3 to the IL-6/OSM response element, while
binding of the AP-1 protein was constitutive. Binding sites
for both AP-1 and STAT3 are necessary for full respon-
siveness of the TIMP-1 promoter to IL-6/OSM, as shown







Figure 2: TIMPs and MMPs in inﬂammation and tumor progres-
sion. TIMPs functions in inhibition of MMP activity, activation of
the proinﬂammatory NF-κB pathway, and regulation of inﬂamma-
tion. MMPs play a critical role in tumor progression. Inﬂammatory
cytokines enhance the dysfunction of MMPs, whereas MMPs
increase inﬂammation in the tissue. TIMPs may modulate critical
signaling pathways for inﬂammation and cancer independent of
metalloproteinase inhibition.
IL-6/OSM response element conferred responsiveness onto
a heterologous promoter [61]. As a downstream target of
STAT3, TIMP1 mediates the antiapoptotic eﬀects of STAT3
[62].
The IL-10 receptor is in the JAK/STAT class of receptors
[63]. IL-10 blocked MMP-2 and MT1-MMP transcription
and protein synthesis in an IL-10 receptor-dependent man-
ner [48]. Therefore, it will be interesting to investigate
whether the regulation of IL-10 on TIMP and MMP is
through the JAK/STAT pathway.
7. Conclusion andFutureStudies
Based on the important role of MMPs cancer and successful
drug trials in mice, numerous clinical trials were initiated in
the 1990s to test the eﬀectiveness of hydroxamic acid-derived
MMP inhibitors (MMPIs) in patients with cancer. However,
these drugs have languished. Retrospective assessment of the
design of clinical trials has led to the recognition that speciﬁc
MMPIs used in conjunction with cytotoxic chemotherapy
in early stage, rather than late stage cancer, needs future
consideration [31]. The important lessons learned from the
MPI experience may be of great value for future studies of
MPIs and for cancer drug development in general [31].
Eempiric evidence for control and modulation of MMP
transcription and/or activation by several naturally occur-
ring substances, such as ﬂavonoids, green tea polyphenols,
and curcumin, represent novel options for the control of
MMP activity even in early tumor stages. Additionally,
these substances have little or no toxic side eﬀects and
good bioavailability, and therefore their continuing analysis
provides intriguing insight into tumor pathophysiology and
possibly new therapeutic options [64].
Increasing evidences demonstrate that TIMPs could
modulate critical signaling pathways independent of metal-
loproteinase inhibition. These ﬁndings suggest that further
understanding of the antiangiogenic activity of TIMPs might
be exploited in human cancer therapy.Journal of Signal Transduction 5
Cytokine and chemokines display diverse eﬀects for
enhancing immunity to tumor-associated antigens, regu-
lating angiogenesis, promoting proliferation/antiapoptosis
of tumor cells, and mediating tumor cell invasion and
traﬃcking in an organ-speciﬁc manner that leads to metas-
tases. They can be seen as important therapeutic targets for
intervention in cancer [65].
Cancer progression is known to be involved in the
NF-κB and STAT pathways. NF-κB is an important target
to prevent metastasis and provide a rationale for further
study of this transcription factor in metastatic disease [66].
TIMPs functions in inhibition of MMP activity, activation
of the proinﬂammatory NF-κB pathway, and regulation of
inﬂammation. MMPs play a critical role in tumor pro-
gression. Inﬂammatory cytokines enhance the dysfunction
of MMPs, whereas MMPs increase inﬂammation in the
tissue (Figure 2). Therefore, understanding inﬂammation
regulated by MMP and TIMP will provide the platform
for the design of therapies. The therapeutic implications of
anti-inﬂammation and anticancer will be an exciting and
promising ﬁeld of translational studies.
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